Lung cancer screening: the way forward

To take lung cancer screening into national programmes, we first have to answer the question whether low-dose computed tomography (LDCT) screening and treatment of early lesions will decrease lung cancer mortality compared with a control group, to accurately estimate the balance of benefits and harm...

Descripción completa

Detalles Bibliográficos
Autores principales: Field, J K, Duffy, S W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527832/
https://www.ncbi.nlm.nih.gov/pubmed/18665179
http://dx.doi.org/10.1038/sj.bjc.6604509
_version_ 1782158845844389888
author Field, J K
Duffy, S W
author_facet Field, J K
Duffy, S W
author_sort Field, J K
collection PubMed
description To take lung cancer screening into national programmes, we first have to answer the question whether low-dose computed tomography (LDCT) screening and treatment of early lesions will decrease lung cancer mortality compared with a control group, to accurately estimate the balance of benefits and harms, and to determine the cost-effectiveness of the intervention.
format Text
id pubmed-2527832
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-25278322009-09-11 Lung cancer screening: the way forward Field, J K Duffy, S W Br J Cancer Minireview To take lung cancer screening into national programmes, we first have to answer the question whether low-dose computed tomography (LDCT) screening and treatment of early lesions will decrease lung cancer mortality compared with a control group, to accurately estimate the balance of benefits and harms, and to determine the cost-effectiveness of the intervention. Nature Publishing Group 2008-08-19 2008-07-29 /pmc/articles/PMC2527832/ /pubmed/18665179 http://dx.doi.org/10.1038/sj.bjc.6604509 Text en Copyright © 2008 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Field, J K
Duffy, S W
Lung cancer screening: the way forward
title Lung cancer screening: the way forward
title_full Lung cancer screening: the way forward
title_fullStr Lung cancer screening: the way forward
title_full_unstemmed Lung cancer screening: the way forward
title_short Lung cancer screening: the way forward
title_sort lung cancer screening: the way forward
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527832/
https://www.ncbi.nlm.nih.gov/pubmed/18665179
http://dx.doi.org/10.1038/sj.bjc.6604509
work_keys_str_mv AT fieldjk lungcancerscreeningthewayforward
AT duffysw lungcancerscreeningthewayforward

Ejemplares similares